Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences Inc. (TLSI) is a biotechnology innovator advancing targeted drug delivery systems and immune-oncology therapies for liver and pancreatic cancers. This page provides authorized updates on clinical developments, financial announcements, and strategic initiatives directly from the company.
Investors and researchers will discover timely updates on TriSalus' Pressure Enabled Drug Delivery (PEDD) technology platform, therapeutic candidate nelitolimod, and TriNav® device advancements. Our curated news collection ensures access to verified press releases, regulatory milestones, and partnership announcements – critical for evaluating the company's progress in oncology innovation.
Content spans clinical trial results, peer-reviewed research publications, executive leadership updates, and manufacturing developments. All materials maintain strict compliance with financial disclosure standards while emphasizing TriSalus' mission to improve treatment outcomes through precision medicine.
Bookmark this page for efficient tracking of TLSI's advancements in merging advanced drug delivery with immune response modulation – a dual approach reshaping oncology care paradigms.
TriSalus Life Sciences (NASDAQ: TLSI) presented clinical data from its Phase 1b PERIO-02 trial at the ASCO 2024 Annual Meeting. The trial studies the hepatic arterial infusion (HAI) of nelitolimod using TriSalus's proprietary Pressure Enabled Drug Delivery (PEDD) technology in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The 4 mg dose showed promising results with all three patients achieving disease control, including one complete response, one partial response, and one stable disease. Follow-up is ongoing to determine the next steps. The PEDD method aims to improve drug delivery within tumor microenvironments, potentially enhancing treatment efficacy. Median progression-free survival for the 4 mg dose was over 120 days. The study also noted significant immune responses, including increased CD4 and CD8 T cells in liver tumors.
TriSalus Life Sciences (NASDAQ: TLSI), an oncology company, announced an exchange offer and consent solicitation for its various warrants. The initiative aims to simplify the capital structure and reduce the dilutive impact of these warrants. Holders of the Public Warrants, Private Placement Warrants, and Working Capital Warrants are offered to exchange their warrants for 0.30 shares of common stock per warrant. If adopted, the Warrant Amendment will require outstanding warrants to be exchanged at 0.27 shares per warrant. The offer involves up to 4,264,532 shares of common stock and seeks consents from warrant holders to amend the warrant agreements. The offer expires on June 25, 2024, and is managed by Oppenheimer & Co. Inc.
TriSalus Life Sciences (Nasdaq: TLSI) reported its Q1 2024 financial results, highlighting a 116% year-over-year revenue increase to $6.5 million, driven by the TriNav® Infusion System. The gross margin improved to 85%, up from 78% in Q1 2023. Despite increased investments leading to an operating loss of $11.7 million and a net loss of $13.2 million, the company secured up to $50 million in debt financing with OrbiMed. Additionally, TriSalus appointed Liselotte Hyveled to its Board of Directors. The company forecasts full-year sales growth to exceed 50%.
TriSalus Life Sciences, a Nasdaq-listed oncology company, appointed Liselotte Hyveled to its Board of Directors. Hyveled, an industry veteran with over two decades of experience in pharmaceutical research and development, will contribute to TriSalus' vision of pioneering innovative treatments for liver and pancreatic cancers. Her strategic insights and patient-centric approach will be important in shaping the company's growth trajectory and advancing its technology and therapeutic pipelines.
TriSalus Life Sciences, a Nasdaq-listed oncology company, will host a conference call on May 15, 2024, at 9:00 a.m. ET to discuss first-quarter financial results and provide a business update. The call will cover the period ending March 31, 2024, and will be webcast live on their investor relations website.
TriSalus Life Sciences has secured up to $50 million in debt financing with OrbiMed to support the growth of its TriNav® Infusion System. $25 million was funded initially, with an option for an additional $25 million based on revenue thresholds. The financing is expected to fuel strategic expansion, extending the cash runway through 2025.
FAQ
What is the current stock price of TriSalus Life Sciences (TLSI)?
What is the market cap of TriSalus Life Sciences (TLSI)?
